Ceftriaxone and Hypoxic-ischaemic encephalopathy - a phase IV clinical study of FDA data

Summary:

Hypoxic-ischaemic encephalopathy is reported as a side effect among people who take Ceftriaxone (ceftriaxone sodium), especially for people who are female, 40-49 old, also take Azithromycin, and have Behcet's syndrome.

The phase IV clinical study analyzes which people have Hypoxic-ischaemic encephalopathy when taking Ceftriaxone. It is created by eHealthMe based on reports of 40,872 people who have side effects when taking Ceftriaxone from the FDA, and is updated regularly.

What is Ceftriaxone?

Ceftriaxone has active ingredients of ceftriaxone sodium. It is often used in typhoid fever. eHealthMe is studying from 40,991 Ceftriaxone users. Check the latest studies of Ceftriaxone.

What is Hypoxic-ischaemic encephalopathy?

Hypoxic-ischaemic encephalopathy (a condition that occurs when the entire brain is deprived of an adequate oxygen supply, but the deprivation isn't total) is found to be associated with 373 drugs and 597 conditions by eHealthMe. Check the latest studies of Hypoxic-ischaemic encephalopathy.

On Jul, 08, 2026

40,872 people reported to have side effects when taking Ceftriaxone.
Among them, 22 people (0.05%) have Hypoxic-ischaemic encephalopathy.

Could Ceftriaxone cause Hypoxic-ischaemic encephalopathy?

Among these 22 people:

What is the gender of people who have Hypoxic-ischaemic encephalopathy when taking Ceftriaxone? *

female: 63.16 %
male: 36.84 %

What is the age of people who have Hypoxic-ischaemic encephalopathy when taking Ceftriaxone? *

What are other drugs people take besides Ceftriaxone? *

What are other side effects people have besides Hypoxic-ischaemic encephalopathy? *

Hypotension (abnormally low blood pressure): 9 people, 40.91%
Cardiac Arrest: 9 people, 40.91%
Bradycardia (abnormally slow heart action): 6 people, 27.27%
Acute Kidney Failure: 6 people, 27.27%
Metabolic Acidosis (body produces too much acid, or when the kidneys are not removing enough acid from the body): 5 people, 22.73%
Pulmonary Oedema (fluid accumulation in the lungs): 5 people, 22.73%
Respiratory Acidosis (respiratory failure or ventilatory failure, causes the ph of blood and other bodily fluids to decrease): 5 people, 22.73%
Heparin-Induced Thrombocytopenia: 4 people, 18.18%
Gangrene (body tissue dies): 4 people, 18.18%
Peripheral Ischaemia (impaired circulation to an extremity): 4 people, 18.18%

What are the existing conditions these people have? *

Pneumonia: 2 people, 9.09%
Osteoporosis (bones weak and more likely to break): 2 people, 9.09%
Nausea And Vomiting: 2 people, 9.09%
Behcet's Syndrome (involves inflammation of the blood vessels): 2 people, 9.09%
Strongyloidiasis (infection with strongyloides stercoralis): 1 person, 4.55%
Engraftment Syndrome (inflammatory condition during neutrophil recovery after hematopoietic stem cell transplantation): 1 person, 4.55%
Acute Lymphocytic Leukemia (All) (cancer of the white blood cells characterized by excess lymphoblasts): 1 person, 4.55%
Back Pain: 1 person, 4.55%
Bacterial Infection: 1 person, 4.55%
Chest Pain: 1 person, 4.55%

* Approximation only. Some reports may have incomplete information.

Do you take Ceftriaxone and have Hypoxic-ischaemic encephalopathy?

- Check whether Hypoxic-ischaemic encephalopathy is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Ceftriaxone:

Ceftriaxone (40,991 reports)

Browse all side effects of Ceftriaxone:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Hypoxic-ischaemic encephalopathy:

Hypoxic-ischaemic encephalopathy (373 drugs)

Browse all the conditions that are associated with Hypoxic-ischaemic encephalopathy:

Hypoxic-ischaemic encephalopathy (597 conditions)

Related publications that referenced our studies

Agrawal SR, Rajput A, Jain AP, "Leukocytoclastic vasculitis and acute allergic interstitial nephritis following ceftriaxone exposure", Journal of pharmacology & pharmacotherapeutics, 2014 Jan .
Agrawal SR, Rajput A, Jain AP, "Leukocytoclastic vasculitis and acute allergic interstitial nephritis following ceftriaxone exposure", Journal of pharmacology & pharmacotherapeutics, 2014 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on ceftriaxone sodium (the active ingredients of Ceftriaxone) and Ceftriaxone (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.